撤稿声明：抑制剂9联合雄激素剥夺疗法或化疗通过K-Ras/PLCε/PKCε信号通路延缓去势抵抗性前列腺癌的恶性行为。
Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway.
出版信息
Front Oncol. 2021 May 31;11:707608. doi: 10.3389/fonc.2021.707608. eCollection 2021.
Abstract
[This retracts the article DOI: 10.3389/fonc.2020.00075.].
摘要
[本文撤回文章DOI: 10.3389/fonc.2020.00075。]
相似文献
1
Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway.
Front Oncol. 2021 May 31;11:707608. doi: 10.3389/fonc.2021.707608. eCollection 2021.
2
Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway.
Front Oncol. 2020 Feb 25;10:75. doi: 10.3389/fonc.2020.00075. eCollection 2020.
3
Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Clin Cancer Res. 2014 Feb 15;20(4):951-61. doi: 10.1158/1078-0432.CCR-13-1809. Epub 2013 Dec 18.
4
Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
J Urol. 2020 Jan;203(1):120-127. doi: 10.1097/JU.0000000000000494. Epub 2019 Aug 20.
5
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Jpn J Clin Oncol. 2021 Apr 1;51(4):544-551. doi: 10.1093/jjco/hyaa225.
6
Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.
J Urol. 2015 Mar;193(3):1023-9. doi: 10.1016/j.juro.2014.09.021. Epub 2014 Sep 19.
7
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
8
Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Int J Urol. 2019 Jan;26(1):62-68. doi: 10.1111/iju.13800. Epub 2018 Sep 20.
9
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.
10
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
Zotero 插件